Welcome to our dedicated page for Catalyst Pharmaceuticals SEC filings (Ticker: CPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Catalyst Pharmaceuticals’ dense biotech filings can feel like wading through clinical-trial data, patent tables, and risk factors that stretch for hundreds of pages. Investors searching for “Catalyst Pharmaceuticals SEC filings explained simply” or wondering how Firdapse® revenue moves the needle quickly discover the documents are anything but short. That’s where Stock Titan steps in.
Our AI-powered engine ingests every 10-K, 10-Q, 8-K, and Form 4 the moment it hits EDGAR, then serves plain-English answers to questions you actually ask: “Catalyst Pharmaceuticals quarterly earnings report 10-Q filing,” “Catalyst Pharmaceuticals proxy statement executive compensation,” or “Catalyst Pharmaceuticals insider trading Form 4 transactions.” Interactive dashboards display “Catalyst Pharmaceuticals Form 4 insider transactions real-time,” while a single view of “Catalyst Pharmaceuticals executive stock transactions Form 4” reveals buying or selling trends before markets react. The platform’s narrative threads drug-sales shifts, R&D spend, and milestone payments into context you can act on.
Because Catalyst’s growth relies heavily on Firdapse® exclusivity and a focused rare-disease pipeline, even a single disclosure can reshape forecasts. Our summaries flag clinical-trial updates, FDA designations, and royalty agreements—“Catalyst Pharmaceuticals 8-K material events explained” without legal jargon. Dive deeper with “Catalyst Pharmaceuticals annual report 10-K simplified,” or launch an “understanding Catalyst Pharmaceuticals SEC documents with AI” walkthrough that pinpoints where orphan-drug incentives surface in the footnotes. Finally, AI-driven charts turn raw numbers into a “Catalyst Pharmaceuticals earnings report filing analysis,” clarifying revenue concentration, cash runway, and dilution risk—no white coat required.
Brian Elsbernd, Chief Compliance/Legal Officer and Director of Catalyst Pharmaceuticals, reported option exercises and an open-market sale on 09/08/2025. He exercised 112,475 options at an exercise price of $2.24 per share, resulting in the acquisition of 112,475 common shares. To fund the exercise price and tax withholding, 30,000 shares were sold on the open market at a weighted average price of $20.30 (sales ranged from $20.225 to $20.315). Following these transactions, Mr. Elsbernd beneficially owned 271,039 shares directly and reported 846,609 derivative securities (options) beneficially owned. The options reported vested in three annual tranches beginning December 19, 2019.
Catalyst Pharmaceuticals (CPRX) filing a Form 144 notifies of a proposed sale of 30,000 common shares to be executed through Fidelity Brokerage Services on 09/08/2025 with an aggregate market value of $609,035.49 based on the filing. The shares were acquired through options granted 12/19/2018 and the reported payment method for the sale is cash. The filing also reports recent open-market disposals by the same person: 20,000 shares sold on 09/03/2025 for $401,514.00 and 30,000 shares sold on 09/04/2025 for $585,642.00. The filer attests no undisclosed material adverse information.
Catalyst Pharmaceuticals insider Brian Elsbernd, listed as the company's Chief Compliance/Legal Officer, reported option exercises and open-market sales on 09/03/2025 and 09/04/2025. He exercised 20,000 options on 09/03/2025 at a $2.24 exercise price and sold 20,000 common shares that day for a weighted average of $20.08 per share. On 09/04/2025 he exercised another 30,000 options at $2.24 and sold 30,000 shares for a weighted average of $19.52 per share. Following these transactions his beneficial ownership in common stock is reported as 188,564 shares and the filing shows remaining option positions underlying 989,084 and 959,084 shares after each exercise event as reported in Table II. The filing states the sales were on the open market for personal reasons and not due to any disagreement with the company.
Catalyst Pharmaceutical, Inc. (CPRX) filing a Form 144 notifies the proposed sale of 30,000 common shares through Fidelity Brokerage Services with an aggregate market value of $585,640.54. The shares represent options granted on 12/19/2018 and were acquired on 09/04/2025; payment is expected in cash. The filing lists 122,391,010 shares outstanding and names NASDAQ as the exchange for an approximate sale date of 09/04/2025. It also discloses a recent sale of 20,000 shares by Brian Elsbernd on 09/03/2025 for gross proceeds of $401,514.00. The filer certifies no undisclosed material adverse information.
Catalyst Pharmaceuticals (CPRX) reports a proposed Rule 144 sale of 20,000 common shares, to be transacted through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $401,514.10. The shares were acquired on 09/03/2025 via exercise of options originally granted on 12/19/2018, and payment for those shares is noted as cash. The filing indicates 122,391,010 shares outstanding for the issuer and states there were no securities sold by the reporting person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Insider transaction summary: Director David S. Tierney exercised stock options to acquire 50,000 shares of Catalyst Pharmaceuticals, Inc. common stock at an exercise price of $2.24 per share on 08/27/2025, resulting in 158,274 stock options/underlying derivative securities held following the transaction. To fund the exercise price and estimated taxes, Mr. Tierney sold 26,000 shares in the open market on the same date at a weighted average price of $20.20 per share (sales ranged from $20.10 to $20.32). After these transactions, Mr. Tierney beneficially owned 379,620 shares of common stock. The Form 4 was signed 08/28/2025.
Steve Miller, Chief Operating & Scientific Officer of Catalyst Pharmaceuticals (CPRX), reported option exercises and an open-market sale. On 08/26/2025 he exercised 115,000 options at an exercise price of $2.24 and sold 115,000 shares at a weighted average price of $20.28 (sales ranged $20.04–$20.645) to fund the exercise price and estimated taxes. After those transactions his reported beneficial ownership moved between 1,064,663 and 949,663 shares. On 08/27/2025 he exercised an additional 110,000 options at $2.24. The Form 4 was signed 08/28/2025.
Richard J. Daly, President and CEO and director of Catalyst Pharmaceuticals, reported exercises and a related sale on August 26, 2025. He exercised 50,000 stock options at an exercise price of $2.24 per share, and concurrently sold 22,970 common shares at $20.62 per share to fund the exercise price and tax withholding. Following these transactions, Mr. Daly reported 226,794 shares beneficially owned directly and reported derivative holdings that underlie 50,000 option shares; the filing lists total derivative-related beneficial ownership of 2,184,753 shares.
Catalyst Pharmaceuticals filed a Form 144 notice indicating a proposed sale of 26,000 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $525,087.81. The filing lists the approximate date of sale as 08/27/2025 and names NASDAQ as the securities exchange. It records the number of shares outstanding as 122,391,010. The securities are reported as acquired by an option granted 12/19/2018 with an acquisition date shown as 08/27/2025, and the consideration on sale noted as cash. Several issuer and filer identification fields in the provided content are blank or not shown in the excerpt.
FAQ
What is the current stock price of Catalyst Pharmaceuticals (CPRX)?
What is the market cap of Catalyst Pharmaceuticals (CPRX)?
